AI-HEART Lab Clinical Tools
2023 ACC/AHA/ACCP/HRS Atrial Fibrillation Guideline Calculator
Guideline-informed decision-support across 13 integrated modules. Classify AF, assess stroke and bleeding risk, select anticoagulation, and guide rhythm and rate control strategies.
HIPAA-Compliant
- Calculator runs 100% in your browser — no patient data is transmitted
- AI features process data under a signed HIPAA BAA with zero data retention
How It Works
Classify AF
Enter patient data to classify AF type (paroxysmal, persistent, long-standing persistent, permanent) and identify the clinical substrate
Assess Risk
Calculate CHA₂DS₂-VASc stroke risk and HAS-BLED bleeding risk to guide anticoagulation decisions
Select Therapy
Choose anticoagulation (DOAC vs warfarin), rate control, rhythm control, catheter ablation, or LAA closure based on patient profile
Manage Comorbidities
Address HF, valvular disease, CKD, obesity, obstructive sleep apnea, and other conditions that impact AF management
Search the LiteratureBeta
HIPAA CompliantResults open in a new tab — your calculator work stays here
Atrial Fibrillation Pathophysiology
Atrial remodeling (electrical and structural), pulmonary vein triggers, autonomic modulation, fibrotic substrate, thrombogenesis in the left atrial appendage, and mechanisms of antiarrhythmic and ablation therapies.
Explore mechanisms →Landmark Trials That Shaped the 2023 AF Guideline
- EAST-AFNET 4: Early rhythm control reduced cardiovascular events in patients with recently diagnosed AF
- CASTLE-AF: Catheter ablation improved survival and reduced HF hospitalization in AF with HFrEF
- RE-LY / ROCKET-AF / ARISTOTLE: DOACs demonstrated non-inferior or superior efficacy to warfarin with lower intracranial hemorrhage rates
- AFIRE: Rivaroxaban monotherapy was superior to dual antithrombotic therapy in patients with stable CAD and AF
Stay Current on Atrial Fibrillation Evidence
— landmark trials and significant new findings, with AI-contextualized summaries
0 of 13 modules completed
IMPORTANT: This software is clinical decision support (CDS) intended for use by licensed healthcare professionals under Section 520(o)(1)(E) of the Federal Food, Drug, and Cosmetic Act. It is not intended as a medical device. All recommendations are derived from the 2023 ACC/AHA/ACCP/HRS Guideline for Diagnosis and Management of Atrial Fibrillation and must be independently verified by the treating clinician before any clinical action. AI-generated content (including extracted data and clinical notes) is produced by large language models and may contain errors, omissions, or hallucinations — clinician review is mandatory. Patient data entered into the calculator is processed entirely in the browser; AI features process data server-side under a signed HIPAA Business Associate Agreement with no data retention. AI-HEART Lab, its affiliates, and contributors assume no liability for clinical decisions made using this tool. By using this tool, you acknowledge these limitations and accept full responsibility for clinical decisions.
Calculator computation is 100% client-side. Opt-in AI features process data server-side under a signed HIPAA BAA with no data retention.
About This Tool
This calculator implements the 2023 ACC/AHA/ACCP/HRS Guideline for Diagnosis and Management of Atrial Fibrillation. Every clinical threshold — AF classification, CHA₂DS₂-VASc scoring, anticoagulation selection, antiarrhythmic drug choice, ablation indications, and rate control targets — is mapped directly to the corresponding guideline figure, table, or recommendation with Class of Recommendation (COR) and Level of Evidence (LOE) cited.
The tool includes 13 core modules covering AF classification and staging, stroke risk assessment, bleeding risk evaluation, DOAC selection with renal dosing, warfarin management, rate control strategy, rhythm control and antiarrhythmic drug selection, catheter ablation, left atrial appendage closure, upstream therapy and risk factor modification, AF in special populations, AF with heart failure, and comorbidity management. Patient data flows between modules — a CHA₂DS₂-VASc score automatically informs anticoagulation recommendations across the tool.
Calculator computation occurs entirely in your browser. Opt-in AI features (data extraction, note generation, email delivery) process clinical data server-side under a signed HIPAA Business Associate Agreement — data is held in memory only and never persisted or logged.
Key Updates in the 2023 AF Guideline
The 2023 ACC/AHA/ACCP/HRS Guideline for Diagnosis and Management of Atrial Fibrillation represents a comprehensive update incorporating new evidence on early rhythm control, expanded ablation indications, DOAC preference, and a new AF staging classification system. Published in Circulation in January 2024, it replaces the 2014 AHA/ACC/HRS AF Guideline.
New AF Staging System
The guideline introduces a four-stage AF classification: Stage 1 (at risk for AF — obesity, hypertension, diabetes, sleep apnea, excessive alcohol), Stage 2 (pre-AF — structural or electrical findings predisposing to AF), Stage 3 (AF — subdivided into 3a paroxysmal, 3b persistent, 3c long-standing persistent, and 3d successful AF ablation), and Stage 4 (permanent AF — rhythm control no longer pursued). This replaces the traditional lone AF terminology and emphasizes AF as a progressive disease requiring risk factor modification at every stage.
Early Rhythm Control
Based on EAST-AFNET 4 trial results, the guideline now endorses early rhythm control as a treatment strategy for patients with recently diagnosed AF (within 1 year). Early intervention with antiarrhythmic drugs or catheter ablation reduced the composite of cardiovascular death, stroke, and HF hospitalization. This represents a paradigm shift from the prior “rate-control-first” approach for many patients.
DOAC Preference Over Warfarin
DOACs (apixaban, rivaroxaban, edoxaban, dabigatran) are now the preferred anticoagulants over warfarin for stroke prevention in non-valvular AF (COR 1, LOE A). Evidence from RE-LY, ROCKET-AF, ARISTOTLE, and ENGAGE AF-TIMI 48 demonstrates comparable or superior efficacy with significantly lower rates of intracranial hemorrhage. Warfarin remains indicated for moderate-to-severe mitral stenosis and mechanical heart valves. DOAC dosing requires renal function-based adjustment, and the guideline provides specific drug-by-drug renal thresholds.
Expanded Catheter Ablation Indications
Catheter ablation is now recommended as a first-line rhythm control option for symptomatic paroxysmal AF (COR 1, LOE A), elevated from its prior role as second-line after AAD failure. For patients with AF and HFrEF, ablation receives a strong recommendation based on CASTLE-AF and CABANA subgroup data showing improved survival, reduced HF hospitalization, and LVEF recovery. The guideline also addresses ablation for persistent AF and emphasizes pulmonary vein isolation as the cornerstone strategy.
Why Use This Calculator
13 Integrated Clinical Modules
Each module maps directly to the guideline's clinical decision algorithms: AF classification and staging, CHA₂DS₂-VASc stroke risk scoring, HAS-BLED bleeding risk assessment, DOAC selection with renal dosing, warfarin management, rate control strategy, rhythm control and antiarrhythmic drug selection, catheter ablation indications, left atrial appendage closure, upstream therapy and risk factor modification, special populations, AF with heart failure, and comorbidity management. Patient data flows between modules — a CHA₂DS₂-VASc score entry automatically informs anticoagulation and LAA closure recommendations.
Privacy and Data Handling
Calculator computation runs entirely in your browser with no server transmission. There are no user accounts, no cookies storing clinical data, and no analytics tracking patient inputs. Opt-in AI features (data extraction, note generation, email delivery) process clinical data server-side under a signed HIPAA Business Associate Agreement — data is held in memory only and never persisted or logged.
Built by a Practicing Cardiologist
This calculator was developed by Dr. Rahul Chaudhary, a practicing cardiologist (FACP, FACC) and physician-scientist with 150+ peer-reviewed publications, 18 international guideline citations, and training at Johns Hopkins University and UPMC, former faculty at Mayo Clinic Rochester. Every clinical threshold is mapped to a specific guideline figure or table with source documentation.
Frequently Asked Questions
What is CHA₂DS₂-VASc scoring?
CHA₂DS₂-VASc is a validated scoring system for estimating annual stroke risk in non-valvular atrial fibrillation. It assigns points for Congestive heart failure (1), Hypertension (1), Age ≥75 (2), Diabetes (1), prior Stroke/TIA/thromboembolism (2), Vascular disease (1), Age 65–74 (1), and Sex category (female, 1). The 2023 guideline recommends oral anticoagulation for men with a score ≥2 and women with a score ≥3 (COR 1, LOE A).
When are DOACs preferred over warfarin?
DOACs are recommended over warfarin for stroke prevention in non-valvular AF (COR 1, LOE A). Apixaban, rivaroxaban, edoxaban, and dabigatran have demonstrated non-inferior or superior efficacy with lower intracranial hemorrhage rates in RE-LY, ROCKET-AF, ARISTOTLE, and ENGAGE AF-TIMI 48 trials. Warfarin remains the standard for moderate-to-severe mitral stenosis and mechanical heart valves. DOAC dosing must account for renal function, with specific CrCl thresholds for each agent.
How are antiarrhythmic drugs selected?
AAD selection depends on underlying cardiac substrate. For patients without significant structural heart disease: flecainide, propafenone, dronedarone, dofetilide, or sotalol. For coronary artery disease: dronedarone, dofetilide, or sotalol. For heart failure: amiodarone or dofetilide. Amiodarone is the most effective AAD but carries risks of thyroid, pulmonary, hepatic, and ocular toxicity requiring ongoing surveillance. Dofetilide requires in-hospital QTc monitoring during initiation.
When is catheter ablation indicated?
Catheter ablation is recommended as a first-line rhythm control option for symptomatic paroxysmal AF (COR 1, LOE A) and after AAD failure. For AF with HFrEF, ablation is recommended based on CASTLE-AF data showing improved survival and LVEF recovery. Pulmonary vein isolation is the cornerstone strategy. The decision should weigh symptom burden, AF duration, left atrial size, operator experience, and patient preference.
Does this calculator store or transmit patient data?
Calculator computation occurs entirely in your browser with no server transmission. Opt-in AI features (data extraction, AI-generated notes, email delivery) process clinical data server-side under a signed HIPAA Business Associate Agreement — data is held in memory only during the request and is never persisted, cached, or logged.
Explore Other Guideline Calculators
Free, guideline-aligned clinical decision support tools
2026 Lipid Guideline Calculator
PREVENT-ASCVD risk scoring, statin treatment cascades, LDL-C goals, and 9 integrated modules.
Open tool →AHA/ACC2025 HTN Guideline Calculator
BP classification, risk-stratified treatment, comorbidity-specific drug selection, and 9 integrated modules.
Open tool →AHA/ACC/HFSA2022 HF Guideline Calculator
HF classification, GDMT optimization, device therapy, special populations, and 13 integrated modules.
Open tool →Shared Decision-Making Tools
Printable patient handouts with personalized risk visualization for lipid-lowering therapy discussions.
Open tool →Reference
Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(1):e1-e156. doi:10.1161/CIR.0000000000001193
Developed by AI-HEART Lab
Built by Dr. Rahul Chaudhary, a physician-scientist with 150+ publications and 18 international guideline citations, trained at Johns Hopkins University and UPMC, former faculty at Mayo Clinic Rochester.